Drug Trial Radar · NCT06819514
The Safety and Efficacy of Intravenous EXG110 in Patients With Fabry Disease
Last checked: Nov 19, 2026Latest source record: Feb 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
16
Planned (sponsor's estimate)
Start
Mar 1, 2025
Primary completion
Mar 15, 2028
Study completion Mar 15, 2028
Sponsor
- Lead sponsor
- Guangzhou Jiayin Biotech LtdIndustry
- Sponsor type
- Industry
- First posted
- Feb 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase 1/2, multicenter, open-label, Dose-escalation study to evaluate the safety and efficacy of intravenous EXG110 in patients with Fabry disease
Conditions
- Fabry Disease
Interventions
EXG110 InjectionDrug
EXG110 Injection is gene therapy for Fabry Disease , uses a proprietary AAV capsid with improved liver and muscle specificity.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: To evaluate the safety and tolerability of EXG110 following a single intravenous infusionTime frame: 52 weeks
- Phase 2: The changes from the baseline of kidney functionTime frame: 6 months
- Phase 2: The changes from the baseline of cardiac functionTime frame: 6 months
- Phase 2: The changes from the baseline of painTime frame: 6 months
- Phase 2: The changes from the baseline of gastrointestinal functionTime frame: 6 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
General Hospital of Eastern Theater Command
Nanjing, Jiangsu, China
Children's Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
First Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.